单中心273例接受去纤苷治疗患者的肝重度静脉闭塞病的发病率及管理 - Suppr

Suppr

超能文献

Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide.

作者信息

Pol R R, Russell N, Das-Gupta E, Watson L, Rachael L, Byrne J

机构信息

BMT Unit, Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.

出版信息

Bone Marrow Transplant. 2016 Sep;51(9):1262-4. doi: 10.1038/bmt.2016.99. Epub 2016 Apr 25.

DOI:10.1038/bmt.2016.99

PMID:27111044

Abstract

摘要

相似文献

Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide.

Bone Marrow Transplant. 2016 Sep;51(9):1262-4. doi: 10.1038/bmt.2016.99. Epub 2016 Apr 25.

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.

Lancet. 2012 Apr 7;379(9823):1301-9. doi: 10.1016/S0140-6736(11)61938-7. Epub 2012 Feb 23.

Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.

Biol Blood Marrow Transplant. 2017 Jun;23(6):997-1004. doi: 10.1016/j.bbmt.2017.03.008. Epub 2017 Mar 8.

Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.

Expert Rev Gastroenterol Hepatol. 2017 Oct;11(10):885-898. doi: 10.1080/17474124.2017.1370372. Epub 2017 Sep 4.

In brief: Defibrotide (Defitelio) for hepatic veno-occlusive disease.

Med Lett Drugs Ther. 2016 Sep 12;58(1503):120.

Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Expert Rev Clin Pharmacol. 2018 Feb;11(2):113-124. doi: 10.1080/17512433.2018.1421943. Epub 2018 Jan 5.

Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2148-2153. doi: 10.1016/j.bbmt.2015.08.013. Epub 2015 Aug 14.

Prophylaxis and treatment of hepatic veno-occlusive disease after pediatric stem cell transplantation.

Haematologica. 2006 Jun;91(6):726B.

Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation.

Br J Haematol. 2020 Aug;190(4):583-587. doi: 10.1111/bjh.16552. Epub 2020 Mar 10.

Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.

Expert Rev Hematol. 2012 Jun;5(3):291-302. doi: 10.1586/ehm.12.18.

引用本文的文献

Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS).

Bone Marrow Transplant. 2019 Dec;54(12):2117-2119. doi: 10.1038/s41409-019-0507-3.

Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS).

Bone Marrow Transplant. 2019 Dec;54(12):1951-1962. doi: 10.1038/s41409-019-0474-8. Epub 2019 Feb 25.

Defibrotide in the treatment of hepatic veno-occlusive disease.

Hepat Med. 2016 Oct 31;8:105-113. doi: 10.2147/HMER.S79243. eCollection 2016.

本文引用的文献

How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation.

Br J Haematol. 2015 Feb;168(4):481-91. doi: 10.1111/bjh.13215. Epub 2014 Nov 17.

Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen.

Bone Marrow Transplant. 2014 Nov;49(11):1389-92. doi: 10.1038/bmt.2014.168. Epub 2014 Jul 28.

BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.

Br J Haematol. 2013 Nov;163(4):444-57. doi: 10.1111/bjh.12558. Epub 2013 Sep 17.

Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1589-99. doi: 10.1016/j.bbmt.2012.04.011. Epub 2012 Apr 21.

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.

Lancet. 2012 Apr 7;379(9823):1301-9. doi: 10.1016/S0140-6736(11)61938-7. Epub 2012 Feb 23.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Blood. 2009 Dec 17;114(26):5264-70. doi: 10.1182/blood-2009-07-234880. Epub 2009 Oct 7.

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Biol Blood Marrow Transplant. 2010 Feb;16(2):157-68. doi: 10.1016/j.bbmt.2009.08.024. Epub 2009 Sep 18.

High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.

Bone Marrow Transplant. 2008 Apr;41(8):721-7. doi: 10.1038/sj.bmt.1705965. Epub 2008 Jan 7.

Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention.

Bone Marrow Transplant. 2004 Jan;33(2):189-95. doi: 10.1038/sj.bmt.1704329.

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients.

Blood. 2004 Jan 1;103(1):78-84. doi: 10.1182/blood-2003-04-1311. Epub 2003 Sep 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验